About Us

The Company

Biocure Technology Inc. is a biopharmaceutical company comprised of leading scientists specializing in the development and commercialization of major biosimilar products.

Founders and management are driven by a social agenda aimed at providing a global answer to highly priced biological medicines that remain outside the reach of common people. The company has unique scientific and execution skills to address the high barriers of Biosimilar pharmaceuticals is well positioned to gain leadership in this growing 40 billion dollar market.

Management & Board

Sang Mok Lee,  CEO & President, Director  

Dr. Lee has been a President and CEO since the inception in 2005. Dr. Lee holds a PhD in microbiology from Busan National University in Korea and is currently an adjunct professor in microbiology at Chungnam National University. Dr. Lee isa committee member for the hi-tech medical complex city in Daejon, Korea and a committee member of KOFST (the Korean Federation of Science and Technology Societies).  

Konstantin Lichtenwald, CFO,  Director  

Mr. Lichtenwald has over ten years of finance and accounting experience, including corporate compliance, accounting and financial management and IPO, RTO services. Mr. Lichtenwald offers extensive knowledge and know-how for companies in two key financial jurisdictions, North America and German speaking parts of Europe. His accounting, financial skills offer a multi-faceted hands on approach to strategic management and problem solving.

Mr. Lichtenwald earned his bachelor of business administration degree from Pforzheim University, Germany, and holds the professional designation of Chartered Professional Accountant (CPA, CGA) and Chartered Certified Accountant (ACCA), where he is a member of Chartered Professional Accountants of B.C. and Canada as well as a member of the Association of Chartered Certified Accountants of United Kingdom. 

Collin (Sang Goo) Kim, Director  

Mr. Kim holds a bachelor degree of business administration from Korea University, Seoul, Korea. Mr. Kim came to Vancouver, Canada in 2006 after working for Hanwha Corp., one of Korean business conglomerates for 16 years, where he was dedicated to International trading business for various industrial products.

He has been working as a Vice President for Columbia Capital since 2008 and a director of ArcPacific Resources Corp., a public Canadian junior exploration company, since 2015. He is imperative in the communication between Korean management and Canadian management cross the border with his vast knowledge and work experience. 

Hans Frykman, Director

Dr. Hans Frykman is the current medical director of Neurocode Labs in Vancouver and UBC Diagnostic Services Lab. Neurocode is world leading in the field of neurogenetis accepting difficult adult and paediatric neurology cases from Asia, North America and Europe.

It is Canada’s first and only clinical whole exome sequencing laboratory. Also, Neurocode has a best in class software product linking genotype to phenotype in the area of neurogenetics. UBC Diagnostic Services Lab is Canada’s leading clinical Neuroimmunology laboratory servicing all provinces with this highly complex testing.Under Dr. Frykman’s guidance, the UBC Diagnostic Services lab has expanded fourfold. Dr. Frykman has a medical degree from Karolinska Institute in Stockholm, a PhD in Biocatalysis at Royal Institute of Technology, and post graduate medical training from Karolinska University Hospital Solna Campus, Mayo Clinic, University of Minnesota, Memorial Sloan Kettering and University of British Columbia in the areas of internal medicine, oncology, clinical pathology, molecular genetics and medical biochemisty.

Dr. Frykman held research positions with the US Government, Astra Zeneca, Akzo Nobel and Novo Nordisk. Early in his career he was part of the discovery teams around Victoza and Losec (Prilosec). He is licensed to practice medicine in Sweden and British Columbia.

Advisory Board


Mr. Shin is a pharmacist and also holds a Ph.D. in Pharmacology from Seoul National University in Korea and is currently an adjunct professor at KonKuk University Medical School. He had worked as a chief of pharmacology & toxicology Lab. in the preclinical development of new drugs in Chong Kun Dang Pharmaceutical Corp. for 21 years. Since 2008, he has been working as a managing director for IL-YANG Pharm. Co. Ltd., being responsible for preclinical and clinical development of new drugs and several vaccines for human and avian influenza. Since 2013, he has also been a member of policy advisory committee of KSAP (The Korean Society of Applied Pharmacology).


Dr. Lee holds Bachelor’s and Master’s degrees in Microbiology from Seoul National University in Korea and a Ph.D. in Environmental Toxicology from Hankuk University of Foreign Studies. For 29 years, he worked on the development of biopharmaceuticals in CJ Inc. and Samsung Group; and conducted nonclinical animal testing and licensing work for drug development in Korea Institute of Toxicology. Currently, he is the vice-president of BiocurePharm, leading the pre-clinical and clinical development of biopharmaceuticals such as interferon beta and CAR-T immune cell therapy products.Since 2011, he has been a member of the Institutional Review Board (IRB) and a Certified Toxicology Professional in Korea.


Dr. Lee holds a Ph.D. in molecular biotechnology form Korea Advanced Institute of Science and Technology in Korea.He has worked as a senior researcher in charge of the development of a variety of biopharmaceuticals in CJ Inc. (1987 ~ 2005), and as Director of research institute of JW Creagene Inc. (2005 ~ 2012) developing immune-cell therapies.He is currently Director of research institute of Pharos Vaccine Inc. and a non-executive director of Aprogen Inc.